News

News and Press Releases
Research | Nutrition UPDATE: FDA Approves Expanded Use of Enzyme Device for Children

The U.S. Food and Drug Administration has approved a device, called RELiZORB®, that helps break down beneficial fats in supplemental nutrition provided via G-tubes.

| 3 min read
Research Cystic Fibrosis Foundation Therapeutics Announces $7.5 Million Award to Discover New Therapies for Nonsense Mutations

A $7.5 million research award will go to Southern Research to identify potential new drugs for people with rare CF mutations, known as nonsense mutations, Cystic Fibrosis Foundation Therapeutics Inc. announced today.

| 2 min read
Research CF Foundation Awards $23M to 11 Sites in its Research Development Program

The Cystic Fibrosis Foundation has awarded more than $23 million across 11 sites in its Research Development Program (RDP), a network of research centers that brings together top-notch scientists from different disciplines to apply their expertise to the challenges of treating cystic fibrosis. 

| 3 min read
Research | CFTR Modulators CF Foundation Celebrates FDA Approval of Orkambi as Important Advance for the CF Community

The Cystic Fibrosis Foundation celebrates the FDA's approval today of the lumacaftor/ivacaftor combination drug (Orkambi™) as an important advance for the cystic fibrosis community. Orkambi targets the underlying cause of the disease in people with two copies of the most common CF gene mutation.

| 4 min read
Research The Brightest Minds in Science, Medicine and Industry Meet to Discuss Advances and Challenges in CF Research

The Cystic Fibrosis Foundation recently hosted the CFF Research Conference: Pushing the Frontiers, bringing together nearly 150 basic scientists, clinical researchers, graduate students and pharmaceutical company representatives to share information on recent advances and critical challenges in CF drug discovery and development.

| 3 min read
Research Cystic Fibrosis Foundation Therapeutics Announces $5 Million Award to Support Development of Anti-Inflammatory Treatment

Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), the nonprofit affiliate of the Cystic Fibrosis Foundation, announced today a $5 million development award to Corbus Pharmaceuticals for a potential new therapy to reduce lung inflammation in people with CF.

| 2 min read
About the CF Foundation | Cystic Fibrosis Foundation Therapeutics (CFFT) | Research Cystic Fibrosis Foundation Therapeutics Announces $14 Million Research Expansion with Genzyme

Program Aimed at Advancing Search for Therapies Targeting Most Common Mutation of CF

| 3 min read
Research Associated Press: Foundation’s Drug Development Model Groundbreaking in Fight against Rare Disease

The Associated Press published a story this week highlighting the Cystic Fibrosis Foundation's "groundbreaking" drug development model and its role in developing CF treatments that target the root cause of the disease.

| 1 min read